GlobeNewswire

Washington's Road User Charge Goes Live

Dela

ISSY LES MOULINEAUX, France, March 12, 2018 (GLOBE NEWSWIRE) -- emovis, the mobility solution provider of the world's leading highway management firm, Abertis, is thrilled to announce the start of the Washington Road User Charge (WARUC) Pilot Project. 

For 12 months, 2,000 volunteers will participate in the pilot in order to experience the replacement of the gas tax by a pay-per-mile travelled charge. Drivers will simulate paying for the miles they drive rather than the gallons of fuel they buy. The results of this year-long trial will help shape the state's future transportation funding policy.

emovis is proud to take part in this initiative that seeks to explore new ways of providing sustainable transportation revenues to maintain critical road infrastructures in the US. This exciting project illustrates emovis' long history of Road Usage Charge projects in the US, where the company is involved in Oregon's RUC Pilot (wwww.myorego.org) as well as similar projects in Europe. emovis is committed to continuous innovation in conceiving smart road-based mobility solutions.

Cloud-based Mobility Solution 
In addition to implementing a cloud-hosted back office solution, emovis provides On-Board Diagnostic (OBD-II) mileage recording devices and smartphone app technology, thanks to its partnership with Automatic®.

Automatic® is a San Francisco based leader in connecting every car on the road to the internet and empowering drivers with knowledge about themselves and their cars. Through this strategic partnership, emovis is leading the way in introducing a commercially available off-the-shelf consumer product and applying it to a road user charge solution.

The Challenge of Out of State Drivers 
As with any state-based road charging program, out-of-state drivers pose a challenge in terms of compliance and revenue enforcement for state road authorities.

One of the key objectives of WARUC is precisely this-to test multi-jurisdictional charging by relying on the location-aware capabilities of the on-board mileage recording devices. The simulated charges applied to the participants' trips differ depending on the location of each recorded mile travelled. All of this is achieved while adhering to strict privacy and data protection guidelines set out by the State.

About WARUC (www.waroadusagecharge.org)
Washington state is testing a Road Usage Charge (WARUC) where drivers simulate paying for miles driven rather than gallons of gas purchased. Various methods of mileage reporting will be tested during this trial. 

This pilot is aimed at exploring new ways to fund the upkeep of roads as states are confronted with fast declining gas tax-based revenues.

In September 2017, following a competitive tender, emovis was selected to provide a turnkey RUC solution in support of the Washington State Transportation Commission's RUC pilot project.

About emovis 
emovis is focused on keeping roads moving through toll-based smart mobility solutions. With over 600 employees worldwide, the company operates some of the world's largest free-flow tolling infrastructure in the UK, Ireland, U.S., and Canada. 

In addition to being awarded the WA RUC project in 2017, emovis successfully launched UK's second All Electronic Tolling near Liverpool (www.merseyflw.co.uk) last October. The company is 100% owned by Abertis (www.abertis.com), the international market leader in the management of toll roads, managing over 5,300 miles (8,600 kilometres) of high capacity and quality roads in 15 countries in Europe, the Americas and Asia.

www.emovis.com
Media Contact: Benoît ROSSI
communication@emovis.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a36cf3b5-7286-4328-9c6c-4da005563877




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: emovis via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum